Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
29
CDT Quote, Financials, Valuation and Earnings
Last price:
$1.52
Seasonality move
:
-36.45%
Day range:
$1.48 - $1.53
52-week range:
$1.24 - $2,198.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.58x
Volume:
20.4K
Avg. volume:
330.3K
1-year change:
-99.85%
Market cap:
$2.5M
Revenue:
--
EPS (TTM):
-$266.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$1.5M | -$0.96 | -7.14% | -109.39% | $52.67 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-- | -$0.68 | -100% | -499.94% | $47.33 |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.62 | -- | -1.78% | $52.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CDT
CDT Equity, Inc.
|
$1.51 | -- | $2.5M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics, Inc.
|
$15.24 | $52.67 | $476.9M | -- | $1.03 | 0% | 24.31x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics, Inc.
|
$38.95 | $47.33 | $1.9B | -- | $0.00 | 0% | 501.13x |
|
ORKA
Oruka Therapeutics, Inc.
|
$26.40 | $52.17 | $1.3B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CDT
CDT Equity, Inc.
|
30.47% | -0.944 | 27% | 1.13x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.162 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
5.99% | 0.000 | 1.94% | 17.36x |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.530 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics, Inc.
|
-$571K | -$33M | -30.65% | -35.16% | -- | -$24.7M |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
CDT Equity, Inc. vs. Competitors
-
Which has Higher Returns CDT or LENZ?
LENZ Therapeutics, Inc. has a net margin of -- compared to CDT Equity, Inc.'s net margin of -133.6%. CDT Equity, Inc.'s return on equity of -- beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital CDTCDT Equity, Inc.-- -$13.16 $6.2M LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About CDT or LENZ?
CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $52.67 which suggests that it could grow by 245.58%. Given that LENZ Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTCDT Equity, Inc.0 0 0 LENZLENZ Therapeutics, Inc.5 0 0 -
Is CDT or LENZ More Risky?
CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CDT or LENZ?
CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CDT or LENZ?
CDT Equity, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. CDT Equity, Inc.'s net income of -$7.1M is higher than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus 24.31x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTCDT Equity, Inc.-- -- -- -$7.1M LENZLENZ Therapeutics, Inc.24.31x -- $12.5M -$16.7M
-
Which has Higher Returns CDT or LIMN?
Liminatus Pharma has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CDTCDT Equity, Inc.-- -$13.16 $6.2M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About CDT or LIMN?
CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that CDT Equity, Inc. has higher upside potential than Liminatus Pharma, analysts believe CDT Equity, Inc. is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings CDTCDT Equity, Inc.0 0 0 LIMNLiminatus Pharma0 0 0 -
Is CDT or LIMN More Risky?
CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CDT or LIMN?
CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CDT or LIMN?
CDT Equity, Inc. quarterly revenues are --, which are larger than Liminatus Pharma quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Liminatus Pharma's net income of --. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTCDT Equity, Inc.-- -- -- -$7.1M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns CDT or MAZE?
Maze Therapeutics, Inc. has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Maze Therapeutics, Inc.'s return on equity of -35.16%.
Company Gross Margin Earnings Per Share Invested Capital CDTCDT Equity, Inc.-- -$13.16 $6.2M MAZEMaze Therapeutics, Inc.-- -$0.63 $403.6M -
What do Analysts Say About CDT or MAZE?
CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Maze Therapeutics, Inc. has an analysts' consensus of $47.33 which suggests that it could grow by 21.52%. Given that Maze Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Maze Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTCDT Equity, Inc.0 0 0 MAZEMaze Therapeutics, Inc.9 0 0 -
Is CDT or MAZE More Risky?
CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maze Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CDT or MAZE?
CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Maze Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CDT or MAZE?
CDT Equity, Inc. quarterly revenues are --, which are smaller than Maze Therapeutics, Inc. quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Maze Therapeutics, Inc.'s net income of -$30.1M. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Maze Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus 501.13x for Maze Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTCDT Equity, Inc.-- -- -- -$7.1M MAZEMaze Therapeutics, Inc.501.13x -- -- -$30.1M
-
Which has Higher Returns CDT or ORKA?
Oruka Therapeutics, Inc. has a net margin of -- compared to CDT Equity, Inc.'s net margin of --. CDT Equity, Inc.'s return on equity of -- beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital CDTCDT Equity, Inc.-- -$13.16 $6.2M ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About CDT or ORKA?
CDT Equity, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $52.17 which suggests that it could grow by 97.6%. Given that Oruka Therapeutics, Inc. has higher upside potential than CDT Equity, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CDTCDT Equity, Inc.0 0 0 ORKAOruka Therapeutics, Inc.11 0 0 -
Is CDT or ORKA More Risky?
CDT Equity, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.394, suggesting its less volatile than the S&P 500 by 139.44%.
-
Which is a Better Dividend Stock CDT or ORKA?
CDT Equity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. CDT Equity, Inc. pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CDT or ORKA?
CDT Equity, Inc. quarterly revenues are --, which are smaller than Oruka Therapeutics, Inc. quarterly revenues of --. CDT Equity, Inc.'s net income of -$7.1M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, CDT Equity, Inc.'s price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CDT Equity, Inc. is -- versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CDTCDT Equity, Inc.-- -- -- -$7.1M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
